Posted by Michael Wonder on 05 Mar 2021
ICER publishes final evidence report and policy recommendations on roxadustat
5 March 2021 - Independent appraisal committee determines the evidence is not adequate to demonstrate that roxadustat provides a net health benefit over erythropoiesis stimulating agents; until greater net benefit is proven, value based pricing would suggest that roxadustat be priced at most at parity with the erythropoiesis stimulating agents.
The ICER today released a Final Evidence Report assessing the comparative clinical effectiveness and value of roxadustat (FibroGen) for treatment of anaemia in chronic kidney disease.
